| Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. | |
| | |
MedLine Citation:
|
PMID: 20554945 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Tamoxifen use has been associated with increased risk of thromboembolic events (TEs) in women with breast cancer and women at high risk for the disease. Factor V Leiden (FVL) is the most common inherited clotting factor mutation and also confers increased thrombosis risk. We investigated whether FVL was associated with TE risk in women with early-stage breast cancer who took adjuvant tamoxifen. METHODS: A case-control study was conducted among 34 Cancer and Leukemia Group B (CALGB) institutions. We matched each of 124 women who had experienced a documented TE while taking adjuvant tamoxifen for breast cancer (but who were not necessarily on a CALGB treatment trial) to two control subjects (women who took adjuvant tamoxifen but did not experience TE) by age at diagnosis (+/-5 years). DNA from blood was analyzed for FVL mutations. Conditional logistic regression was used to estimate odds ratios (ORs) and to evaluate other potential factors associated with TE and tamoxifen use. All P values are based on two-sided tests. RESULTS: FVL mutations were identified in 23 (18.5%) case and 12 (4.8%) control subjects (OR = 4.66, 95% confidence interval = 2.14 to 10.14, P < .001). In the multivariable model, FVL mutation was associated with TE (OR = 4.73, 95% confidence interval = 2.10 to 10.68, P < .001). Other statistically significant factors associated with TE risk were personal history of TE and smoking. CONCLUSIONS: Among women taking adjuvant tamoxifen for early-stage breast cancer, those who had a TE were nearly five times more likely to carry a FVL mutation than those who did not have a TE. Postmenopausal women should be evaluated for the FVL mutation before prescription of adjuvant tamoxifen if a positive test would alter therapeutic decision making. |
| | |
Authors:
|
Judy E Garber; Susan Halabi; Sara M Tolaney; Ellen Kaplan; Laura Archer; James N Atkins; Stephen Edge; Charles L Shapiro; Lynn Dressler; Electra D Paskett; Electra M Paskett; Gretchen Kimmick; James Orcutt; Anthony Scalzo; Eric Winer; Ellis Levine; Nasir Shahab; Nancy Berliner; |
Related Documents
:
|
21495075 - Hypertension is a potential risk factor for vascular dementia: systematic review. 20730665 - Online support groups for women with metastatic breast cancer: a feasibility pilot study. 19544685 - Breast cancer in women under 40. 1868735 - Oral contraceptives and breast cancer: review of the epidemiologic literature. 16619595 - Spatiotemporal patterns of host-seeking ixodes scapularis nymphs (acari: ixodidae) in t... 20618345 - The association between the ratio of visceral fat to thigh muscle area and metabolic sy... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2010-06-16 |
Journal Detail:
|
Title: Journal of the National Cancer Institute Volume: 102 ISSN: 1460-2105 ISO Abbreviation: J. Natl. Cancer Inst. Publication Date: 2010 Jul |
Date Detail:
|
Created Date: 2010-07-07 Completed Date: 2010-07-14 Revised Date: 2011-08-01 |
Medline Journal Info:
|
Nlm Unique ID: 7503089 Medline TA: J Natl Cancer Inst Country: United States |
Other Details:
|
Languages: eng Pagination: 942-9 Citation Subset: IM |
Affiliation:
|
Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA. judy_garber@dfci.harvard.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Antineoplastic Agents, Hormonal / administration & dosage, adverse effects* Breast Neoplasms / drug therapy* Case-Control Studies Chemotherapy, Adjuvant Estrogen Receptor Modulators / administration & dosage, adverse effects* Factor V / genetics* Female Humans Logistic Models Middle Aged Multivariate Analysis Mutation* Odds Ratio Prevalence Risk Factors Selective Estrogen Receptor Modulators / adverse effects Smoking / adverse effects Tamoxifen / administration & dosage, adverse effects* Thromboembolism / chemically induced, etiology*, genetics, prevention & control |
| Grant Support | |
ID/Acronym/Agency:
|
CA02599/CA/NCI NIH HHS; CA03927/CA/NCI NIH HHS; CA04457/CA/NCI NIH HHS; CA12046/CA/NCI NIH HHS; CA12449/CA/NCI NIH HHS; CA21060/CA/NCI NIH HHS; CA31946/CA/NCI NIH HHS; CA32291/CA/NCI NIH HHS; CA33601/CA/NCI NIH HHS; CA35113/CA/NCI NIH HHS; CA37447/CA/NCI NIH HHS; CA41287/CA/NCI NIH HHS; CA45389/CA/NCI NIH HHS; CA45418/CA/NCI NIH HHS; CA45808/CA/NCI NIH HHS; CA47577/CA/NCI NIH HHS; CA47642/CA/NCI NIH HHS; CA60138/CA/NCI NIH HHS; CA77406/CA/NCI NIH HHS; CA77597/CA/NCI NIH HHS; CA77658/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents, Hormonal; 0/Estrogen Receptor Modulators; 0/Selective Estrogen Receptor Modulators; 0/factor V Leiden; 10540-29-1/Tamoxifen; 9001-24-5/Factor V |
| Comments/Corrections | |
Comment In:
|
J Natl Cancer Inst. 2010 Jul 7;102(13):918-9
[PMID:
20554943
]
|
Erratum In:
|
J Natl Cancer Inst. 2010 Aug 4;102(15):1210 Note: Paskett, Electra M [corrected to Paskett, Electra D] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Essential Role of TRPC6 Channels in G2/M Phase Transition and Development of Human Glioma.
Next Document: N-Glycosylation engineering of lepidopteran insect cells by the introduction of the beta1,4-N-acetyl...